Cargando…
Association of Hepatobiliary Phase of Gadoxetic-Acid-Enhanced MRI Imaging with Immune Microenvironment and Response to Atezolizumab Plus Bevacizumab Treatment
SIMPLE SUMMARY: High intensity of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced MRI imaging (EOB-MRI) in the hepatobiliary phase (HB) is associated with mutations in CTNNB1 and activation of β-catenin, an immune-cold microenvironment, and an unfavorable response...
Autores principales: | Tamura, Yosuke, Ono, Atsushi, Nakahara, Hikaru, Hayes, Clair Nelson, Fujii, Yasutoshi, Zhang, Peiyi, Yamauchi, Masami, Uchikawa, Shinsuke, Teraoka, Yuji, Uchida, Takuro, Fujino, Hatsue, Nakahara, Takashi, Murakami, Eisuke, Tsuge, Masataka, Serikawa, Masahiro, Miki, Daiki, Kawaoka, Tomokazu, Okamoto, Wataru, Imamura, Michio, Nakamura, Yuko, Awai, Kazuo, Kobayashi, Tsuyoshi, Ohdan, Hideki, Fujita, Masashi, Nakagawa, Hidewaki, Chayama, Kazuaki, Aikata, Hiroshi, Oka, Shiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486496/ https://www.ncbi.nlm.nih.gov/pubmed/37686510 http://dx.doi.org/10.3390/cancers15174234 |
Ejemplares similares
-
Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib
por: Fujii, Yasutoshi, et al.
Publicado: (2021) -
Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma
por: Yamauchi, Masami, et al.
Publicado: (2020) -
Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinoma
por: Yamauchi, Masami, et al.
Publicado: (2023) -
Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
por: Yano, Shigeki, et al.
Publicado: (2023) -
Evaluation of Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma Using the Combination of Response Evaluation Criteria in Solid Tumors and Alpha-Fetoprotein
por: Kinami, Takahiro, et al.
Publicado: (2023)